Possible clinical outcome measures for clinical trials in patients with multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 4, 2010, Pages 229-239

  Goldman, Myla D ^a   Motl, Robert W ^b   Rudick, Richard A ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

accelerometry; EDSS; MSFC; multiple sclerosis; outcome measures; six minute walk

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PLACEBO;

ACCELEROMETRY; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; WALKING;

EID: 77954914068     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610374117     Document Type: Review

References (97)

1. Achiron, A., Barak, Y. and Rotstein, Z. ( 2003) Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis. Mult Scler 9: 486-491.
2. Achiron, A. and Fredrikson, S. (2009) Lessons from randomized direct comparative trials. J Neurol Sci 277: s19-s24.
3. Ada, L., Dean, C., Hall, J., Bampton, J. and Crompton, S. ( 2003) A treadmill and overground walking program improves walking in persons residing in the community after stroke: a placebo-controlled, randomized trial. Arch Phys Med Rehab 84: 1486-1491.
4. Bar-Zohar, D., Agosta, F., Goldstaub, D. and Filippi, M. ( 2008) Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 14: 719-727.
5. Bejaoui, K. and Rolak, L. (2010) What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74: 900-902.
6. Bermel, R., Fisher, E. and Cohen, J. ( 2008) The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. Neuroimag Clin North Am 18: 687-701.
7. Brochet, B., Deliore, M., Bonnet, M., Salort-Campana, E., Ouallet, J., Petry, K. et al. (2008) Should the SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler 14: 1242-1249.
8. Butland, R.J.A., Pang, J., Gross, E.R., Woodcock, A.A. and Gedes, D.M. ( 1982) Two-, six-, and twelve-Minute walking test in respiratory disease. Br Med J 284: 1007-1008.
9. Cella, D.F., Dineen, K., Aranson, B., Reder, A., Webster, K.A., Karabatsos, G. et al. (1996) Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47: 129-139.
10. Chetta, A., Rampello, A., Marangio, E., Merlini, S., Dazzi, F., Aiello, M. et al. (2004) Cardiorespiratory response to walk in multiple sclerosis patients. Respir Med 98: 522-529.
11. Cohen, J.A., Cutter, G.R., Fischer, J.S., Goodman, A.D., Heidenreich, F.R., Jak, A.J. et al. (2001) Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58: 961-967.
12. Cohen, J.A., Cutter, G.R., Fischer, J.S., Goodman, A.D., Heidenreich, F.R., Kooijmans, M.F. et al. (2002) Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology 59: 679-687.
13. Cohen, J.A., Fischer, J.S., Bolibrush, D.M., Jak, A.J., Kniker, J.E., Mertz, L.A. et al. (2000) Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 54: 802-806.
14. Confavreux, C., Vukusic, S., Moreau, T. and Adeleine, P. ( 2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430-1438.
15. Cutter, G.R., Baier, M.L., Rudick, R.A., Cookfair, D.L., Fischer, J.S., Petkau, J. et al. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122: 871-882.
16. Daly, J.J., Roenigk, K., Holcomb, J., Rogers, J.M., Butler, K., Gansen, J. et al. (2006) A randomized controlled trial of functional neuromuscular stimulation in chronic stroke subjects. Stroke 37: 172-178.
17. Daumer, M., Neuhause, O., Morrissey, S., Hintzen, R. and Ebers, G. (2009) MRI as an outcome in multiple sclerosis in clinical trials. Neurology 72: 705-711.
18. Dean, C., Richards, C. and Malouni, F. ( 2000) Task related circuit training improves locomotor tasks in chronic stroke. Arch Phys Med Rehab 81: 409-417.
19. Drake, A., Weinstock-Guttman, B., Morrow, S., Hojnacki, D., Munschauer, F. and Benedict, R. (2010) Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 16: 228-237.
20. Duncan, P., Studenski, S., Richards, L., Gollub, S., Lai, S.M., Reker, D. et al. (2000) Randomized clinical trial of therapeutic exercise in subacute stroke. Stroke 34: 2173-2180.
21. Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A. et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 359: 1453-1460.
22. Ebers, G., Heigehauser, L., Daumer, M., Lederer, C. and Noseworthy, J. ( 2008) Disability as an outcome in MS clinical Trials. Neurology 71: 624-631.
23. Fischer, J.S., Rudick, R.A., Cutter, G.R., Reingold, S.C. and the National MS Society Clinical Outcomes Assessment Task Force (1999) The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 5: 244-250.
24. Frohman, E. ( 2003) Multiple Sclerosis. Med Clin North America 87: 867-897.
25. Garber, C. and Friedman, J. ( 2003) Effects of fatigue on physical activity and function in patients with Parkinson's Disease. Neurology 60: 1119-1124.
26. Gauthier, S., Mandel, M., Guttmann, C., Glanz, B., Khoury, S., Betensky, R. et al. (2007) Predicting short-term disability in multiple sclerosis. Neurology 68: 2059-2066.
27. Gijbels, D., Alders, G., van Hoof, E., Charlier, C., Roelants, M., Broekmans, T. et al. (2010) Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler 16 (5): 618-626.
28. Goldman, M., Marrie, R. and Cohen, J. ( 2008) Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 14: 383-390.
29. Hartung, H.-P., Gonsette, R. and the MIMS-Study Group. (1998) Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European Phase III multicenter study - Clinical results (abstract). Mult Scler 4: 325.
30. Hawker, K., O'Connor, P., Freedman, M., Calabresi, P., Antel, J., Simon, J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471.
31. Heesen, C., Böhm, J., Reich, C., Kasper, J., Goebel, M. and Gold, S. ( 2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14: 988-991.
32. Hobart, J., Freeman, J. and Thompson, A. ( 2000) Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 123: 1027-1040.
33. Hobart, J., Lamping, D., Fitzpatrick, R., Riazi, A. and Thompson, A. ( 2001) The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure. Brain 124: 962-973.
34. Hobart, J., Riazi, A., Lamping, D., Fitzpatrick, R. and Thompson, A. ( 2003) Measuring the impact of MS on walking ability. Neurology 60: 31-36.
35. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285-294.
36. Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276.
37. Kalkers, N.F., Bergers, L., de Groot, V., Lazeron, R.H.C., van Walderveen, M.A.A., Uitehaag, B.M.J. et al. (2001) Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 56: 215-219.
38. Kalkers, N.F., de Groot, V., Lazeron, R.H.C., Killestein, J., Ader, H.J., Barkhof, F. et al. (2000) MS functional composite. Relation to disease phenotype and disability strata. Neurology 54: 1233-1239.
39. Kierkegaard, M. and Tollbäck, A. ( 2007) Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromusc Disord 17: 943-949.
40. Kragt, J., Nielsen, J., van der Linden, F., Uitdehagg, B. and Polman, C. ( 2006a) How similar are commonly combined criteria for EDSS progression in multiple sclerosis. Mult Scler 12: 782-786.
41. Kragt, J., Thompson, A., Montalban, X., Tintore, M., Rio, J., Polman, C. et al. (2008) Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology 70: 1084-1091.
42. Kragt, J., van der Linden, F., Nielsen, J., Uitdehagg, B. and Polman, C. ( 2006b) Clinical impact of 20& worsening on Timed 25-foot Walk and 9-hole Peg Test in Multiple Sclerosis. Mult Scler 12: 594-598.
43. Krapf, H., Morrissey, S.P., Zenker, O., Gonsette, R., Hartung, H.-P. and the MIMS-Study Group (1998) Mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European Phase III multicenter study-MRI results (abstract). Mult Scler 4: 380.
44. Krupp, L., LaRocca, N., Muir-Nash, J. and Steinberg, A. ( 1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46: 1121-1123.
45. Kurtzke, J.F. ( 1961) On the evaluation of disability in multiple sclerosis. Neurology 11: 686-694.
46. Kurtzke, J.F. ( 1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33: 1444-1452.
47. Liu, C., Li Wan, P. and Blumhardt, L. ( 1998) ‘Summary measure; statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. JNNP 64: 726-729.
48. Lublin, F.D. and Reingold, S.C. ( 1996) Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46: 907-911.
49. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassman, H. ( 2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717.
50. Martin, C., Phillips, B., Kilpatrick, T., Butzkueven, H., Turbridy, N. and McDonald, E. ( 2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12: 620-628.
51. Mayr, W., Pittock, S., McClelland, R., Jorgensen, N., Noseworthy, J. and Rodriguez, M. ( 2003) Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota: 1985-2000. Neurology 61: 1373-1377.
52. Miller, D.M., Rudick, R.A., Cutter, G., Baier, M. and Fischer, J.S. ( 2000) Clinical significance of the Multiple Sclerosis Functional Composite. Relationship to patient-reported quality of life. Arch Neurol 57: 1319-1324.
53. Montes, J., McDermott, M., Martens, W., Dunaway, S., Glanzman, A., Riley, S. et al. (2010) Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74: 833-838.
54. Motl, R. and McAuley, E. (2009) Longitudinal analysis of physical activity and symptoms as predictors of change in functional limitations and disability in multiple sclerosis. Rehab Psychol 54: 204-210.
55. Motl, R., McAuley, E., Snook, E. and Gliottoni, R.C. (2009 a) Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psycol Health Med 14: 111-124.
56. Motl, R., Snook, E., Wynn, D. and Vollmer, T. ( 2008) Physical activity correlates with neurological impairment and disability in multiple sclerosis. J Nerv Ment Dis 196: 492-495.
57. Motl, R.W., Schwartz, C.E. and Vollmer, T. (2009 b) Continued validation of the Symptom Inventory in multiple sclerosis. J Neurol Sci 285: 134-136.
58. Motl, R.W. and Snook, E.M. ( 2008) Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12). J Neurol Sci 268: 69-73.
59. Narayana, P., Roxburgh, R., Seaman, S., Masterman, T., Hensiek, A., Sawcer, S. et al. (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64: 1144-1151.
60. Page, W., Kurtzke, J., Murphy, F. and Norman, J. ( 1993) Epidemiology of multiple sclerosis in the US veterans: V. ancestry and the risk of multiple sclerosis. Ann Neurol 33: 632-639.
61. Paltamaa, J., Sarasoja, T., Leskinen, E., Wikstrom, J. and Malkia, E. ( 2007) Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehab 88: 1649-1656.
62. Paltamaa, J., Sarasoja, T., Leskinen, E., Wikstrom, J. and Malkia, E. ( 2008) Measuring deterioration in international classification of functioning domains of people with multiple sclerosis who are ambulatory. Phys Therapy 88: 176-190.
63. Pascual, A., Bosca, I., Coret, F., Escutia, M., Bernat, B. and Casanova, B. ( 2008) Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and expanded disability status scale. Eur J Neurol 15: 284-288.
64. Pearson, O., Busse, M., van Deursen, R. and Wiles, C. (2004) Quantification of walking mobility in neurological disorders. QJM 97: 463-475.
65. Polman, C., O'Connor, P., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
66. PRISMS Study Group (1998) Randomized double-blind placebo-controlled study of interferon β-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498-1504.
67. Ritvo, P.G., Fischer, J.F., Miller, D.M., Andrews, H., Paty, D. and LaRocca, N.G. ( 1997) Multiple Sclerosis Quality of Life Inventory: A User's Manual, National Multiple Sclerosis Society: New York.
68. Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J. et al. (1996) Clinical outcomes assessment in multiple sclerosis. Ann Neurol 40: 469-479.
69. Rudick, R., Antel, J., Confavreux, C., Cutter, G., Ellison, G., Fischer, J. et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 42: 379-382.
70. Rudick, R., Cutter, G. and Reingold, S. ( 2002) The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis. Mult Scler 8: 359-365.
71. Rudick, R., Lee, J., Cutter, G., Miller, D., Bourdette, D., Weinstock-Guttman, B. et al. (2010) Significance of disability progression in a clinical trial in relapsing-remitting multiple sclerosis: Eight year follow-up. Arch Neurol, in press.
72. Rudick, R., Lee, J., Nakamura, K. and Fisher, E. (2009 a) Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 282: 106-111.
73. Rudick, R. and Miller, D. ( 2008) Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs 22: 827-839.
74. Rudick, R., Polman, C., Cohen, J., Walton, M., Miller, A., Confavreux, C. et al. (2009 b) Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 15: 984-997.
75. Rudick, R., Stuart, W., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon-β1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
76. Savci, S., Inal-Ince, S., Arikan, H., Guclu-Gunduz, A., Cetisli-Korkmaz, N., Armutlu, K. et al. (2005) Six minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehab 27: 1365-1371.
77. Schumacher, G.A., Beebe, G.W., Kibler, R.F., Kurland, L.T., Kurtzke, J.F., McDowell, F. et al. (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 122: 552-568.
78. Schwid, S., Thornton, C., Pandya, S., Manzur, K., Sanjak, M., Petrie, M. et al. (1999) Quantitative assessment of motor fatigue and strength in MS. Neurology 53: 1294-1296.
79. Schwid, S.R., Goodman, A.D., Apatoff, B.R., Coyle, P.K., Jacobs, L.D., Krupp, L.B. et al. (2000 a) Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 55: 1901-1903.
80. Schwid, S.R., Goodman, A.D., Apatoff, B.R., Coyle, P.K., Jacobs, L.D., Krupp, L.B. et al. (2000 b) Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology 55: 1901-1903.
81. Schwid, S.R., Goodman, A.D., Mattson, D.H., Mihai, C., Donohue, K.M., Petrie, M.D. et al. (1997) The measurement of ambulatory impairment in multiple sclerosis. Neurology 49: 1419-1424.
82. Schwid, S.R., Goodman, A.D., McDermott, M.P., Bever, C.F. and Cook, S.D. ( 2002) Quantitative functional measures in MS: what is a reliable change? Neurology 58: 1294-1296.
83. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 56: 1496-1504.
84. Sharrack, B. and Hughes, R. ( 1999) The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 5: 223-233.
85. Sharrack, B., Hughes, R., Soudain, S. and Dunn, G. ( 1999) The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 122: 141-159.
86. Snook, E., Motl, R. and Gliottoni, R. (2009) The effect of walking mobility on the measurement of physical activity using accelerometry in multiple sclerosis. Clin Rehabil 23: 248-258.
87. Sormani, M., Bonzano, L., Roccatagliata, L., Cutter, G., Mancardi, G. and Bruzzi, P. (2009 a) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65: 268-275.
88. Sormani, M., Rovaris, M., Comi, G. and Filippi, M. (2009 b) A reassessment of the plateauing relationship between T 2 lesion load and disability in MS. Neurology 73: 1538-1542.
89. The IFNB Multiple Sclerosis Study Group (1993 ) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
90. Tremlett, H., Yousefi, M., Devonshire, V., Rieckmann, P., Zhao, Y. and Neurologists, U. (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73: 1616-1623.
91. van Winsen, L., Kragt, J., Hoogervorst, E., Polman, C. and Uitdehagg, B. (2010) Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler 16 (5): 604-610.
92. Ware, J.E., Snow, K.K., Kosinski, M. and Gandek, B.( 1993) SF-36 Health Survey: manual and interpretation guide, The Health Institute, New England Medical Center: Boston, MA.
93. Weikert, M., Motl, R., Suh, Y., McAuley, E. and Wynn, D. (2010) Accelerometry in persons with multiple sclerosis: measurement of physical activity or walking mobility? J Neurol Sci 290: 6-11.
94. Weinshenker, B.G., Bass, B., Rice, G.P.A., Noseworthy, J., Carriere, W., Baskerville, J. et al. (1989 a) The natural history of multiple sclerosis: A geographically based study 2. Predictive value of the early clinical course. Brain 112: 1419-1428.
95. Weinshenker, B.G., Bass, B., Rice, G.P.A., Noseworthy, J., Carriere, W., Baskerville, J. et al. (1989 b) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112: 133-146.
96. Weinshenker, B.G., Rice, G.P.A., Noseworthy, J.H., Carriere, W., Baskerville, J. and Ebers, G.C. ( 1991) The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114: 1057-1067.
97. Wolinsky, J., Narayana, P., O'Connor, P., Coyle, P., Ford, C., Johnson, K. et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61: 14-24.